Clinical trialNCT07061951RecruitingPhase 2Interventional

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

SponsorNational Cancer Institute (NCI)Enrollment20Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jennifer R Brown
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
Benjamin M. Heyman
Recruiting
City of Hope at Irvine Lennar
Irvine, California, United States
Benjamin M. Heyman
Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Sheila Firoozan
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Jennifer R. Brown
Recruiting
Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Deborah M. Stephens
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Kerry A. Rogers
Recruiting
University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
John C. Byrd
Recruiting
Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Margaret K. Baron
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 May 2026
Primary completion: 1 Feb 2030
Completion: 1 Feb 2030
Last update posted: 18 Jun 2026
Registered enrollment: 20
Registry id: NCT07061951

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.